ArticleFrontiers in pharmacology2022

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody.

Tingting Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.